The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | A study assessing the impact of time in patients with LBCL who are candidates for CAR T-cell therapy
Leyre Bento De Miguel, MD, Son Espases University Hospital, Palma de Mallorca, Spain, outlines the results from a multicenter study assessing the impact of time on patients with large B-cell lymphoma (LBCL) who are candidates for CAR T-cell therapy. Dr Bento De Miguel highlights that delays between indication and infusion negatively affect patient outcomes, but as centers gain more experience with the CAR-T process, these time periods are decreasing. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is another really interesting study that we have done on behalf of the Spanish transplant and lymphoma groups, focusing on the different time periods during all the patient journey, the CAR-T journey. So we know that CAR T-cell therapy is really an effective treatment. But as you know, it’s not like an off the shelf, like, for example, bispecific antibodies that you can use at the moment...
So this is another really interesting study that we have done on behalf of the Spanish transplant and lymphoma groups, focusing on the different time periods during all the patient journey, the CAR-T journey. So we know that CAR T-cell therapy is really an effective treatment. But as you know, it’s not like an off the shelf, like, for example, bispecific antibodies that you can use at the moment. So there are some steps that you need to have. And unfortunately, because of all the organization and all the procedures that you have to do, there are so many patients that maybe could not achieve the infusion. And the main reason in the majority of the patients is the progression of the disease. So with this study, our objective was to analyze the different steps. I mean, all the time between the indication and approval, from approval to apheresis, from apheresis to the reception of the product, and also from the reception to the infusion, and to see if there is an impact of these longer times in survival and in overall mortality. And we confirm also that these times have shortened in the last years. So I think that we have like a learning curve and also we specifically in Spain have more centers, infusion centers. So I think that with these improvements, we have improved the results but there are still a lot of things to improve. We need to shorten more and more these periods because we confirmed that these times have a real impact on survival. So I think that is a really interesting study. And we will still, I mean, we will improve the results and we will do some sub-analyses to continue to study the impact of the time and the specific time periods.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
